SCHEMBL1684663

SCHEMBL1684663

Cc1nc2ccccn2c1-c1ccnc(Nc2cccc(O)c2)n1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 15/20 0.78
CDK4 P11802 8/20 0.78
CCNE1 P24864 5/20 0.78
CACNA1B Q00975 1/20 0.65
APBA1 Q02410 1/20 0.65
KLF5 Q13887 1/20 0.65
KDR P35968 2/20 0.59
PLK1 P53350 2/20 0.59
AURKB Q96GD4 2/20 0.59
PTK2 Q05397 1/20 0.59
CDK1 P06493 1/20 0.57
SYK P43405 2/20 0.53
PRKD3 O94806 2/20 0.53
FLT3 P36888 2/20 0.53
GSK3A P49840 2/20 0.53
GSK3B P49841 2/20 0.53
TAOK1 Q7L7X3 2/20 0.53
CLK4 Q9HAZ1 2/20 0.53
IRAK4 Q9NWZ3 2/20 0.53
PLK4 O00444 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL409700 0.88 CDK2 (0.61) CDK2CDK4CCNE1CACNA1BAPBA1
SCHEMBL1684617 0.87 CDK2 (0.78) CDK2CDK4CCNE1CACNA1BAPBA1
SCHEMBL7981339 0.86 CDK2 (0.75) CDK2CDK4CCNE1KDRPLK1
SCHEMBL1684719 0.85 CDK2 (0.74) CDK2CDK4CCNE1CACNA1BAPBA1
SCHEMBL7978545 0.84 CDK2 (0.69) CDK2CDK4CCNE1KDRPLK1
SCHEMBL700587 0.84 CDK2 (0.69) CDK2CDK4CCNE1KDRPLK1
SCHEMBL1684643 0.83 CDK2 (0.86) CDK2CDK4CCNE1KDRPTK2
SCHEMBL1684709 0.81 CDK2 (0.83) CDK2CDK4CCNE1CDK1PRKD3
SCHEMBL1684885 0.81 CDK2 (0.83) CDK2CDK4CCNE1CDK1PRKD3
SCHEMBL1684889 0.81 CDK2 (1.00) CDK2CDK4CCNE1KDRPLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP claimed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US claimed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US claimed
EP-2306836-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2011-04-13 EP claimed
WO-2010002985-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2010-01-07 WO claimed
EP-3111956-B1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2019-05-08 EP disclosed
EP-3111956-A1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2017-01-04 EP disclosed
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP disclosed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US disclosed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS BMI1, CREBBP, BAZ2A CDK2 1442/4885CDK4 1500/4885CCNE1 2093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.